Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors
about
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignanciesPerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsMisfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.ATOH1 Can Regulate the Tumorigenicity of Gastric Cancer Cells by Inducing the Differentiation of Cancer Stem Cells.BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cellsSelective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 AcetylationRunx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia developmentAn immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Epigenetics in the hematologic malignancies.Emerging approaches for histone deacetylase inhibitor drug discovery.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1.Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.How do tumor cells respond to HDAC inhibition?Panobinostat for the treatment of acute myelogenous leukemia.Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.Developing a Novel Indolocarbazole as Histone Deacetylases Inhibitor against Leukemia Cell Lines.Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.Natural Agents-Mediated Targeting of Histone Deacetylases.Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning.Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.RUNX1-ETO Leukemia.Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation
P2860
Q26739689-7F0B9C35-F477-4880-96D2-B930F89EC8F5Q26991440-6565E44E-F7CD-4AA5-A939-3385526C580AQ30374671-2E2FEF97-E4E0-4553-B63F-4341A2F280C6Q34663691-0FD067E7-3332-416E-B61E-856A3D00AD73Q35018971-DADE47B0-BFA9-4231-940A-0BFD133EFC54Q35287823-788CA720-BE44-4A82-9DE3-5BB45AD7E15EQ35581773-AC3080A6-FCAC-4273-8FDD-358CDEF063B2Q36232141-1E892504-5B00-493C-BFD2-224A558E0337Q36242646-BCA8BB4D-8C03-4DFD-A344-DD75D284A4FEQ36259601-355AFD6F-08E4-4BBD-BA12-3BC22AFFA7D9Q36437137-3B9FE807-4C9B-4426-B6B5-A358487CCC10Q36751751-490C00BF-A22F-4CF8-AB73-3414B3DBBB9AQ37277238-282D5AD8-28ED-4B71-BA53-66ACCA27115CQ37536821-114CDF87-039C-4D96-B7D0-316D5F9AEDA2Q38232465-07B886A2-8A43-47E3-B70E-B0A683572FF0Q38240733-7F9D88B1-FC76-45BE-8932-75E23E5278D0Q38282809-32B6F0B5-8C12-4709-BB33-F33B42071731Q38431356-62001105-95C5-414D-BF96-833A30C75F79Q38537883-D0EF246F-ED71-4B4D-A913-08203A9516DCQ38679327-29720D17-BD65-440E-9FC3-790215D8E1E1Q38710509-49C459AF-F4D2-4CEE-8AF8-795F552FA37DQ38738895-95D5AA17-A41F-4A42-8C65-38EAD0FC9CE6Q38739798-47FFA8CC-B8A5-4C3A-BDA6-32FBAED55C39Q38768286-41F68A72-86C0-4FB9-B025-7ED74DEB21BDQ38791113-1B69CC6E-BD1E-486A-9DD0-6B151B8201C7Q38817005-81EA475D-8437-4FAE-81C7-781A44E5B22BQ38835113-51C8671E-A63C-4294-A16E-51F67F2F0546Q39175714-430EF7DE-8357-4B68-842E-032DA223D34CQ39954100-41574A14-7DF6-4001-932B-5C36425151C8Q40153567-D01527F8-7693-4FE2-9A4E-FB9AA0EED5C1Q41065264-291F5F4C-A236-4AD9-BCE5-5AF723C881E1Q41344917-CFB1C633-973D-4169-8DB0-675CE6F8517EQ47740361-3CB37470-45CD-44C8-A2B2-7E9D9778BD3AQ47912546-1CA80389-4EBE-4BCB-8A2B-D0010E77D0F9Q49419358-62286C44-356D-4B86-9A05-C252B11461A1Q49833698-AAD31478-B013-4D52-8297-EE725C4FF68DQ51097627-15852973-1BC0-4E04-AFAA-C8129BCA53EAQ51415557-C9425192-1A7F-4668-89EB-7AA459AD2A52Q51645804-15CB5B95-0FE9-4E6D-B946-1B9B477D2A82Q58116307-B01DA5C1-5569-425F-BC8B-672DA356F1F9
P2860
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Differentiation therapy for the treatment of t
@nl
Differentiation therapy for th ...... histone deacetylase inhibitors
@ast
Differentiation therapy for th ...... histone deacetylase inhibitors
@en
type
label
Differentiation therapy for the treatment of t
@nl
Differentiation therapy for th ...... histone deacetylase inhibitors
@ast
Differentiation therapy for th ...... histone deacetylase inhibitors
@en
prefLabel
Differentiation therapy for the treatment of t
@nl
Differentiation therapy for th ...... histone deacetylase inhibitors
@ast
Differentiation therapy for th ...... histone deacetylase inhibitors
@en
P2093
P2860
P50
P1433
P1476
Differentiation therapy for th ...... histone deacetylase inhibitors
@en
P2093
Adele Baker
Amy R Rappaport
Benjamin P Martin
Gert J Ossenkoppele
Inge Verbrugge
Kym Stanley
Margherita Ghisi
Michael Bots
Peter Atadja
Scott W Lowe
P2860
P304
P356
10.1182/BLOOD-2013-03-488114
P407
P577
2014-01-10T00:00:00Z